BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

883 related articles for article (PubMed ID: 17158546)

  • 1. Targeted therapy for metastatic renal cell carcinoma.
    Motzer RJ; Bukowski RM
    J Clin Oncol; 2006 Dec; 24(35):5601-8. PubMed ID: 17158546
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sunitinib, sorafenib and mTOR inhibitors in renal cancer.
    Radulovic S; Bjelogrlic SK
    J BUON; 2007 Sep; 12 Suppl 1():S151-62. PubMed ID: 17935273
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Signaling inhibitors in metastatic renal cell carcinoma.
    Escudier B
    Cancer J; 2008; 14(5):325-9. PubMed ID: 18836338
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Progress in the management of advanced renal cell carcinoma (RCC).
    Tong TQ; Rohde D; Peter S
    Aktuelle Urol; 2010 Jan; 41 Suppl 1():S57-60. PubMed ID: 20094957
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improvement in survival end points of patients with metastatic renal cell carcinoma through sequential targeted therapy.
    Calvo E; Schmidinger M; Heng DY; Grünwald V; Escudier B
    Cancer Treat Rev; 2016 Nov; 50():109-117. PubMed ID: 27664394
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent advances in the treatment of renal cell carcinoma and the role of targeted therapies.
    Chowdhury S; Larkin JM; Gore ME
    Eur J Cancer; 2008 Oct; 44(15):2152-61. PubMed ID: 18829302
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular biology of renal cell carcinoma.
    Mellado B; Gascón P
    Clin Transl Oncol; 2006 Oct; 8(10):706-10. PubMed ID: 17074668
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Interdisciplinary recommendations for the treatment of metastatic renal cell carcinoma].
    Miller K; Bergmann L; Jäger E; Jakse G; Wirth M; Keilholz U;
    Aktuelle Urol; 2009 Jan; 40(1):27-30. PubMed ID: 19177318
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New therapeutic approaches in the management of metastatic renal cell carcinoma.
    Gkialas IK; Papadopoulos G
    J BUON; 2009; 14(3):399-404. PubMed ID: 19810129
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metastatic renal cell cancer treatments: an indirect comparison meta-analysis.
    Mills EJ; Rachlis B; O'Regan C; Thabane L; Perri D
    BMC Cancer; 2009 Jan; 9():34. PubMed ID: 19173737
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted therapies for the treatment of metastatic renal cell carcinoma: clinical evidence.
    Hutson TE
    Oncologist; 2011; 16 Suppl 2(Suppl 2):14-22. PubMed ID: 21346036
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systemic therapy for metastatic renal cell carcinoma.
    Kroog GS; Motzer RJ
    Urol Clin North Am; 2008 Nov; 35(4):687-701; ix. PubMed ID: 18992622
    [TBL] [Abstract][Full Text] [Related]  

  • 13. VEGF-targeted therapy in renal cell carcinoma: active drugs and active choices.
    Rini BI
    Curr Oncol Rep; 2006 Mar; 8(2):85-9. PubMed ID: 16507216
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Newly approved therapies for RCC and their effect on the standard of care.
    Figlin RA
    Clin Adv Hematol Oncol; 2007 Jan; 5(1):35-6, 66. PubMed ID: 17339824
    [No Abstract]   [Full Text] [Related]  

  • 15. Targeted therapies in metastatic renal cancer in 2009.
    Bastien L; Culine S; Paule B; Ledbai S; Patard JJ; de la Taille A
    BJU Int; 2009 May; 103(10):1334-42. PubMed ID: 19338565
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting von Hippel-Lindau pathway in renal cell carcinoma.
    Patel PH; Chadalavada RS; Chaganti RS; Motzer RJ
    Clin Cancer Res; 2006 Dec; 12(24):7215-20. PubMed ID: 17189392
    [TBL] [Abstract][Full Text] [Related]  

  • 17. von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma.
    Choueiri TK; Vaziri SA; Jaeger E; Elson P; Wood L; Bhalla IP; Small EJ; Weinberg V; Sein N; Simko J; Golshayan AR; Sercia L; Zhou M; Waldman FM; Rini BI; Bukowski RM; Ganapathi R
    J Urol; 2008 Sep; 180(3):860-5; discussion 865-6. PubMed ID: 18635227
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment options in renal cell carcinoma: past, present and future.
    Oudard S; George D; Medioni J; Motzer R
    Ann Oncol; 2007 Sep; 18 Suppl 10():x25-31. PubMed ID: 17761720
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Molecular basis of targeted therapy in metastatic renal cancer].
    Moch H
    Pathologe; 2008 Nov; 29 Suppl 2():184-6. PubMed ID: 18751979
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel kinase inhibitors in renal cell carcinoma: progressive development of static agents.
    Desai AA; Stadler WM
    Curr Oncol Rep; 2005 Mar; 7(2):116-22. PubMed ID: 15717945
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 45.